Results 1 to 10 of about 62,912 (312)

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

New England Journal of Medicine, 2022
BACKGROUND Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as compared with a tumor necrosis factor (TNF ...
Deepak L Bhatt, Roy M Fleischmann
exaly   +2 more sources

Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study

RMD Open, 2023
Objectives Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, were evaluated in a 6-month, double-blind, phase 3 study in Chinese patients with active (polyarthritic) psoriatic arthritis (PsA) and inadequate response to ≥1 conventional ...
Xiaofeng Zeng, Cunshan Wang, Yi Liu, Jian Xu, Ju Liu, Zhuoli Zhang, Wenfeng Tan, Shengyun Liu, Wei Lin, Weiguo Wan, Zhenyu Jiang, Zhiyi Zhang, Oluwaseyi Dina, Shixue Liu, XiaoMei Leng, Keith Kanik, Jiankang Hu, Jingyang Li, Levent M. Gunay, Cassandra Kinch   +19 more
doaj   +2 more sources

Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial [PDF]

Rheumatology and Therapy, 2023
Introduction This post hoc analysis of phase 2 trial data assessed the efficacy of tofacitinib on magnetic resonance imaging (MRI) outcomes with the detailed anatomy-based Canada–Denmark (CANDEN) MRI scoring system and evaluated tofacitinib suppression ...
Mikkel Østergaard, Joseph Wu, Lara Fallon, Sarah P. Sherlock, Cunshan Wang, Dona Fleishaker, Keith S. Kanik, Walter P. Maksymowych   +7 more
doaj   +2 more sources

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus

Nature Communications, 2021
Increased risk of premature cardiovascular disease (CVD) is well recognized in systemic lupus erythematosus (SLE). Aberrant type I-Interferon (IFN)-neutrophil interactions contribute to this enhanced CVD risk.
Sarfaraz A Hasni, Sarthak Gupta, Philip M Carlucci   +2 more
exaly   +2 more sources

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

Nature Communications, 2022
Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with glucocorticoids. An imprecise understanding of the immunologic changes underlying sarcoidosis has limited therapeutic progress.
William Damsky, Alice Wang, Michael J Murphy   +2 more
exaly   +2 more sources

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry

ACR Open Rheumatology, 2021
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease ...
Joel M. Kremer, Clifton O. Bingham III, Laura C. Cappelli, Jeffrey D. Greenberg, Ann M. Madsen, Jamie Geier, Jose L. Rivas, Alina M. Onofrei, Christine J. Barr, Dimitrios A. Pappas, Heather J. Litman, Kimberly J. Dandreo, Andrea B. Shapiro, Carol A. Connell, Arthur Kavanaugh   +14 more
doaj   +2 more sources

Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study

RMD Open
Objectives Compare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in Oral ...
Arne Yndestad, Maya H Buch, Carol A Connell, Kenneth Kwok, Ted Mikuls, Deepak L Bhatt, Jon T Giles, Christina Charles-Schoeman, Gary G Koch, Edward Nagy, Steven Ytterberg, Hyejin Jo, Karim Richard Masri   +12 more
doaj   +2 more sources

Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study

Journal of Translational Medicine
Background Treatment strategy against immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) frequently requires other immunosuppressive agents.
Qing Liu, Mengling Liu, Zhiguo Zou, Jinyi Lin, Ningping Zhang, Lin Zhao, Jiahua Zhou, Haojie Zhou, Xin Zhou, Xiaodong Jiao, Yiyi Yu, Tianshu Liu   +11 more
doaj   +2 more sources

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

New England Journal of Medicine, 2017
Bruce E Sands, Geert D'Haens, Séverine Vermeire   +2 more
exaly   +3 more sources

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study

RMD Open, 2023
Objective To investigate sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis.Methods Patients who had an inadequate response to methotrexate (MTX) with or without biological disease-modifying ...
Yuko Kaneko, Hideto Kameda, Yoshiya Tanaka, Satoshi Kubo, Koichi Amano, Shingo Nakayamada, Yusuke Miyazaki, Kiyoshi Matsui, Yoshino Inoue, Kunihiro Yamaoka, Takehisa Ogura   +10 more
doaj   +1 more source